Aggressive Non-Hodgkin Lymphoma
Information
- Disease name
- Aggressive Non-Hodgkin Lymphoma
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03749018 | Active, not recruiting | Phase 2 | Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma | January 2, 2019 | July 31, 2024 |
| NCT03035331 | Active, not recruiting | Phase 1/Phase 2 | Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma | March 27, 2017 | August 2024 |
| NCT03458260 | Active, not recruiting | Phase 2 | Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma | March 26, 2018 | March 2025 |
| NCT01231412 | Completed | Phase 3 | Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant | November 2010 | June 30, 2017 |
| NCT01251575 | Completed | Phase 2 | Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant | December 1, 2010 | February 11, 2019 |
| NCT01527045 | Completed | Phase 2 | Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies | September 25, 2012 | April 2019 |
| NCT03061188 | Completed | Phase 1 | Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma | May 23, 2017 | August 4, 2020 |
| NCT03161054 | Completed | Phase 2 | Metronomic Chemotherapy in Elderly Non-fit Patients With Aggressive B-Cell Lymphomas | September 12, 2017 | June 21, 2021 |
| NCT00075478 | Completed | Phase 3 | Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer | October 2003 | February 2, 2014 |
| NCT00723099 | Completed | Phase 2 | Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer | June 25, 2008 | July 31, 2018 |
| NCT00789776 | Completed | Phase 1/Phase 2 | Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer | October 13, 2008 | May 2017 |
| NCT05336409 | Recruiting | Phase 1 | A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies | January 24, 2023 | August 2027 |
| NCT05260957 | Recruiting | Phase 2 | CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL). | December 14, 2022 | December 2027 |
| NCT01787409 | Recruiting | N/A | Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency | March 6, 2013 | March 28, 2025 |
| NCT03246906 | Recruiting | Phase 2 | Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation | September 11, 2017 | October 11, 2026 |
| NCT04231877 | Suspended | Phase 1 | Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma | October 27, 2020 | December 1, 2031 |
| NCT03704714 | Suspended | Phase 1/Phase 2 | Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma | November 20, 2018 | June 11, 2025 |
| NCT04372641 | Withdrawn | Phase 1 | Testing the Safety of CB-5339 in Patients With Cancer | June 18, 2020 | July 12, 2021 |